Guidelines for the diagnosis and treatment of malignant pleural mesothelioma

Journal of Thoracic Disease

Volumn 5, Issue 6, 2013, Pages

  van Zandwijk, Nico ^a   Clarke, Christopher ^a   Henderson, Douglas ^b   Musk, A William ^f,p   Fong, Kwun ^c,d   Nowak, Anna ^e,f   Loneragan, Robert ^g   McCaughan, Brian ^a,h   Boyer, Michael ^a   Feigen, Malcolm ⁱ   Currow, David ^j   Schofield, Penelope ^k   Ivimey, Beth ^l   Pavlakis, Nick ^m,n   McLean, Jocelyn ^h   Marshall, Henry ^d   Leong, Steven ^d   Keena, Victoria ^a   Penman, Andrew ^o  

^a UNIVERSITY OF SYDNEY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d THE PRINCE CHARLES HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^g ANZAC Research Institute   (Australia)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

ⁱ AUSTIN HOSPITAL   (Australia)

^j CANCER INSTITUTE NSW   (Australia)

^k PETER MACCALLUM CANCER CENTRE   (Australia)

^l PRINCE OF WALES HOSPITAL   (Australia)

^m ROYAL NORTH SHORE HOSPITAL   (Australia)

ⁿ Scientific Advisory Committee of the Australian Lung Cancer Trials Group   (Australia)

^o Cancer Council   (Australia)

^p UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALRETININ; CARBOPLATIN; CISPLATIN; CYTOKERATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE; GEMCITABINE; MESOTHELIN; MITOMYCIN; MONOCLONAL ANTIBODY; NAVELBINE; PEMETREXED; PLATINUM COMPLEX; PODOPLANIN; RALTITREXED; THYROID TRANSCRIPTION FACTOR 1; VINBLASTINE; WT1 PROTEIN;

ARTICLE; BENIGN TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CYTOPATHOLOGY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOSCOPIC ECHOGRAPHY; EVIDENCE BASED MEDICINE; EXTRAPLEURAL PNEUMONECTOMY; FOLLOW UP; HEALTH CARE DELIVERY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; KINESIOTHERAPY; LUNG RESECTION; MEDIASTINOSCOPY; MENTAL HEALTH CARE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL ASSESSMENT; PLEURA BIOPSY; PLEURA MESOTHELIOMA; PLEURECTOMY; PLEURODESIS; PRACTICE GUIDELINE; PROTEIN EXPRESSION; PSYCHOSOCIAL CARE; PUBLICATION; THORACOSCOPY; THORAX RADIOGRAPHY; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; VIDEO ASSISTED THORACOSCOPIC SURGERY;

EID: 84892398743     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.11.28     Document Type: Article

References (348)

1. Procedures and requirements for meeting the 2011 NHMRC standard for clinical practice guidelines. version 1.1 ed. Melbourne: National Health and Medical Research Council, 2011.
2. Leigh J, Driscoll T. Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health 2003;9:206-17.
3. Musk AW, de Klerk NH. Epidemiology of malignant mesothelioma in Australia. Lung Cancer 2004;45 Suppl 1:S21-3.
4. Mesothelioma in Australia Incidence 1982 to 2007 Mortality 1997 to 2007. Safe Work Australia, 2011:1-20. Available online: http://www.safeworkaustralia.gov.au/sites/swa/aboutsafeworkaustralia/whatwedo/publications/pages/Mesothelioma-in-Australia-2011.aspx
5. Henderson DW, Whitaker D, Shilkin KB. The differential diagnosis of malignant mesothelioma: a practical approach to diagnosis during life. In: Henderson DW, Shilkin KB, Langlois SLP, et al. eds. Malignant mesothelioma. New York: Hemisphere, 1992:184.
6. Attanoos RL, Gibbs AR. Primary malignant gonadal mesotheliomas and asbestos. Histopathology 2000;37:150-9.
7. Clement PB, Young RH, Scully RE. Malignant mesotheliomas presenting as ovarian masses: a report of nine cases, including two primary ovarian mesotheliomas. Am J Surg Pathol 1996;20:1067-80.
8. Asbestos. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Geneva: WHO Press, 1977:1-106.
9. Asbestos (Chrysotile, Amosite, Crocidolite, Tremolite, Actinolite, and Anthophyllite). Arsenic, Metals, Fibres, and Dusts 100 C. Geneva: WHO Press, 2012:219-310.
10. Metintas M, Hillerdal G, Metintas S. Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort. Eur Respir J 1999;13:523-6.
11. Dodson RF, Williams MG Jr, Corn CJ, et al. Asbestos content of lung tissue, lymph nodes, and pleural plaques from former shipyard workers. Am Rev Respir Dis 1990;142:843-7.
12. Asbestos: elimination of asbestos-related diseases. Fact sheet N°343 World Health Organisation, 2010. Available online: http://www.who.int/mediacentre/factsheets/fs343/en/index.html (cited 26 Oct 2011).
13. Van der Schoot HC. Asbestosis&pleural tumors. Ned Tijdschr Geneeskd 1958;102:1125-6.
14. Weiss A. Pleurakrebs bei lungenasbestose, in vivo morphologisch gesichert. Medizinische 1953;1:93-4.
15. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960;17:260-71.
16. Rake C, Gilham C, Hatch J, et al. Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer 2009;100:1175-83.
17. Pan XL, Day HW, Wang W, et al. Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med 2005;172:1019-25.
18. Maule MM, Magnani C, Dalmasso P, et al. Modeling mesothelioma risk associated with environmental asbestos exposure. Environ Health Perspect 2007;115:1066-71.
19. De Bruin ML, Burgers JA, Baas P, et al. Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood 2009;113:3679-81.
20. Tsao AS, Wistuba I, Roth JA, et al. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-90.
21. Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010;35:479-95.
22. Iwatsubo Y, Pairon JC, Boutin C, et al. Pleural mesothelioma: dose-response relation at low levels of asbestos exposure in a French population-based case-control study. Am J Epidemiol 1998;148:133-42.
23. Hillerdal G. Mesothelioma: cases associated with non-occupational and low dose exposures. Occup Environ Med 1999;56:505-13.
24. Hyland RA, Ware S, Johnson AR, et al. Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia. Scand J Work Environ Health 2007;33:286-92.
25. Lin RT, Takahashi K, Karjalainen A, et al. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 2007;369:844-9.
26. Australian Mesothelioma Registry 1st Annual Report Mesothelioma in Australia 2011Safe Work Australia. Available online: www.mesothelioma-australia.com (cited 1 Oct 2012).
27. Aiello Bowles EJ, Tuzzio L, Wiese CJ, et al. Understanding high-quality cancer care: a summary of expert perspectives. Cancer 2008;112:934-42.
28. Ensuring Quality Cancer Care. Washington, DC: National Academy Press, 1999. Available online: http://www.nap.edu/openbook.php?record_id=6467&page=R1 (cited 15 Sept 2011).
29. Driscoll TR, Baker GJ, Daniels S, et al. Clinical aspects of malignant mesothelioma in Australia. Aust N Z J Med 1993;23:19-25.
30. ESMO Guidelines Working Group, Manegold C. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18 Suppl 2:ii34-5.
31. Stahel RA, Weder W, Lievens Y, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v126-8.
32. Rice D, Rusch V, Pass H, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 2011;6:1304-12.
33. Lianes P, Remon J, Bover I, et al. SEOM guidelines for the treatment of malignant pleural mesothelioma. Clin Transl Oncol 2011;13:569-73.
34. Pinto C, Ardizzoni A, Betta PG, et al. Expert opinions of the first italian consensus conference on the management of malignant pleural mesothelioma. Am J Clin Oncol 2011;34:99-109.
35. Ettinger DS, Akerley W, Borghaei H, et al. Malignant pleural mesothelioma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2012;10:26-41.
36. NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. NHMRC. 2009. Available online: http://www.nhmrc.gov.au/guidelines/resources-guideline-developers (cited 1 Feb 2010).
37. Musk AW, De Klerk N, Eccles JL, et al. Malignant mesothelioma in Pilbara Aborigines. Aust J Public Health 1995;19:520-2.
38. Moerman LC, van der Laan SL. The Baryulgil Mine: Asbestos and Aboriginality. Paper prepared for presentation at AIRA, 2010, Sydney 2010. Available online: http://apira2010.econ.usyd.edu.au/conference_proceedings/APIRA-2010-066-Moerman-Accountability-asbestos-and-indigenous-rights.pdf (cited 15 Sept 2011).
39. Yates DH, Corrin B, Stidolph PN, et al. Malignant mesothelioma in south east England: Clinicopathological experience of 272 cases. Thorax 1997;52:507-12.
40. Churg A, Roggli V, Galateau-Salle F. Mesothelioma. In: Travis WD, Brambilla E, Muller-Hermelink HK, et al. eds. Pathology&Genetics: Tumours of the Lung Pleura, Thymus and Heart. Lyon: IARC Press, 2004:128-36.
41. Galateau-Sallé F. eds. Pathology of Malignant Mesothelioma. London: Springer-Verlag, 2010.
42. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007;62 Suppl 2:ii1-ii19.
43. Aerts JG, Delahaye M, van der Kwast TH, et al. The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant. Diagn Cytopathol 2006;34:523-7.
44. Hammar SP, Henderson DW, Klebe S, et al. Neoplasms of the pleura. In: Tomashefski JF Jr. eds. Dail and Hammar's Pulmonary Pathology. Third ed II: Neoplastic Lung Disease. New York: Springer, 2008:558-734.
45. Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: A consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009;133:1317-31.
46. Maskell NA, Gleeson FV, Davies RJ. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet 2003;361:1326-30.
47. Metintas M, Ak G, Dundar E, et al. Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. Chest 2010;137:1362-8.
48. Zahid I, Sharif S, Routledge T, et al. What is the best way to diagnose and stage malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg 2011;12:254-9.
49. Adams RF, Gleeson FV. Percutaneous image-guided cutting-needle biopsy of the pleura in the presence of a suspected malignant effusion. Radiology 2001;219:510-4.
50. Greillier L, Cavailles A, Fraticelli A, et al. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. Cancer 2007;110:2248-52.
51. Rahman NM, Gleeson FV. Image-guided pleural biopsy. Curr Opin Pulm Med 2008;14:331-6.
52. Medford AR, Agrawal S, Free CM, et al. A local anaesthetic video-assisted thoracoscopy service: prospective performance analysis in a UK tertiary respiratory centre. Lung Cancer 2009;66:355-8.
53. Bueno R, Reblando J, Glickman J, et al. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg 2004;78:1774-6.
54. Attanoos RL, Gibbs AR. The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma. Histopathology 2008;53:340-4.
55. Kao SC, Yan TD, Lee K, et al. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. J Thorac Oncol 2011;6:602-5.
56. Henderson DW, Shilkin KB, Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 1998;110:397-404.
57. Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000;24:1183-200.
58. Whitaker D. The cytology of malignant mesothelioma. Cytopathology 2000;11:139-51.
59. Renshaw AA, Dean BR, Antman KH, et al. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 1997;111:106-9.
60. Welker L, Muller M, Holz O, et al. Cytological diagnosis of malignant mesothelioma - Improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch 2007;450:455-61.
61. Cury PM, Butcher DN, Corrin B, et al. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol 1999;189:251-7.
62. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 2003;43:231-8.
63. King J, Thatcher N, Pickering C, et al. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology 2006;49:561-8.
64. Saad RS, Cho P, Liu YL, et al. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol 2005;32:156-9.
65. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007;20:215-20.
66. Monaco SE, Shuai Y, Bansal M, et al. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol 2011;135:619-27.
67. Chiosea S, Krasinskas A, Cagle PT, et al. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 2008;21:742-7.
68. Chung CT, Santos Gda C, Hwang DM, et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol 2010;63:630-4.
69. Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: A clinical-pathologic correlation of 326 cases. Mod Pathol 2010;23:470-9.
70. Klebe S, Mahar A, Henderson DW, et al. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. Mod Pathol 2008;21:1084-94.
71. Mangano WE, Cagle PT, Churg A, et al. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: A histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. Am J Clin Pathol 1998;110:191-9.
72. Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems. Thorax 2000;55:731-5.
73. Neumann V, Rutten A, Scharmach M, et al. Factors influencing long-term survival in mesothelioma patients--results of the German mesothelioma register. Int Arch Occup Environ Health 2004;77:191-9.
74. Schramm A, Opitz I, Thies S, et al. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. Eur J Cardiothorac Surg 2010;37:566-72.
75. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007;2:957-65.
76. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-52.
77. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 1988;6:147-53.
78. Cury PM, Butcher DN, Fisher C, et al. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 2000;13:107-12.
79. Klebe S, Nurminen M, Leigh J, et al. Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies. Pathology 2009;41:140-8.
80. Sheibani K, Shin SS, Kezirian J, et al. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma. Am J Surg Pathol 1991;15:779-84.
81. Dejmek A, Hjerpe A. Carcinoembryonic antigen-like reactivity in malignant mesothelioma: A comparison between different commercially available antibodies. Cancer 1994;73:464-9.
82. Skov BG, Lauritzen AF, Hirsch F, et al. The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: Reproducibility of the histopathological diagnosis. Histopathology 1994;24:553-7.
83. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis. Cytopathology 2000;11:8-17.
84. Dejmek A, Hjerpe A. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn Cytopathol 2005;32:160-6.
85. Hirano T, Gong Y, Yoshida K, et al. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer. 2003;41:155-62.
86. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010;41:20-5.
87. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 1989;13:276-91.
88. Wirth PR, Legier J, Wright GL Jr. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer 1991;67:655-62.
89. Collins CL, Schaefer R, Cook CD, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Eur Respir Rev 1993;3:59-60.
90. Miettinen M, Kvatich AJ. HBME-1: a monoclonal antibody useful in the differential diagnosis of mesothelioma, adenocarcinoma and soft tissue and bone tumor. AppL Immunohistochem 1995;3:115.
91. Gotzos V, Vogt P, Celio MR. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract 1996;192:137-47.
92. Donna A, Betta PG, Chiodera P, et al. Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies. Hum Pathol 1997;28:929-37.
93. Kennedy AD, King G, Kerr KM. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. J Clin Pathol 1997;50:859-62.
94. Ordóñez NG. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Am J Surg Pathol 1997;21:1399-408.
95. Riera JR, Astengo-Osuna C, Longmate JA, et al. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 1997;21:1409-19.
96. Wick MR. Immunophenotyping of malignant mesothelioma. Am J Surg Pathol 1997;21:1395-8.
97. Di Loreto C, Puglisi F, Di Lauro V, et al. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Cancer Lett 1998;124:73-8.
98. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000;36:341-7.
99. Attanoos RL, Webb R, Dojcinov SD, et al. Malignant epithelioid mesothelioma: anti-mesothelial marker expression correlates with histological pattern. Histopathology 2001;39:584-8.
100. Comin CE, Novelli L, Boddi V, et al. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol 2001;32:529-36.
101. Foster MR, Johnson JE, Olson SJ, et al. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 2001;125:1316-20.
102. Roberts F, McCall AE, Burnett RA. Malignant mesothelioma: A comparison of biopsy and postmortem material by light microscopy and immunohistochemistry. J Clin Pathol 2001;54:766-70.
103. Wick MR, Moran CA, Mills SE, et al. Immunohistochemical differential diagnosis of pleural effusions, with emphasis on malignant mesothelioma. Curr Opin Pulm Med 2001;7:187-92.
104. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 2002;15:6-10.
105. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 2003;27:150-8.
106. Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-28.
107. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005;18:105-10.
108. Granville LA, Younes M, Churg A, et al. Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma. Appl Immunohistochem Mol Morphol 2005;13:75-9.
109. Saad RS, Lindner JL, Lin X, et al. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement. Diagn Cytopathol 2006;34:801-6.
110. Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006;19:514-23.
111. Hinterberger M, Reineke T, Storz M, et al. D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol 2007;20:248-55.
112. Mimura T, Ito A, Sakuma T, Ohbayashi C, et al. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer 2007;109:933-8.
113. Hanna A, Pang Y, Bedrossian CW, et al. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. Diagn Cytopathol 2010;38:264-9.
114. Tot T. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas. Cancer 2001;92:2727-32.
115. Powell G, Roche H, Roche WR. Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma. Histopathology 2011;59:950-6.
116. Duhig EE, Kalpakos L, Yang IA, et al. Mesothelial markers in high-grade breast carcinoma. Histopathology 2011;59:957-64.
117. Kushitani K, Takeshima Y, Amatya VJ, et al. Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry. Pathol Int 2008;58:75-83.
118. Takeshima Y, Amatya VJ, Kushitani K, et al. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. Histopathology 2009;54:667-76.
119. Attanoos RL, Dojcinov SD, Webb R, et al. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology 2000;37:224-31.
120. Greillier L, Baas P, Welch JJ, et al. Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther 2008;12:375-90.
121. Benjamin H, Lebanony D, Rosenwald S, et al. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn 2010;12:771-9.
122. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6.
123. Creaney J, Robinson BW. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am 2005;19:1025-40, v.
124. Robinson BW, Creaney J, Lake R, et al. Soluble mesothelin-related protein--a blood test for mesothelioma. Lung Cancer 2005;49 Suppl 1:S109-11.
125. Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 2006;12:4225-31.
126. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-60.
127. Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007;132:1239-46.
128. Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007;13:5076-81.
129. Scherpereel A, Lee YC. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007;13:339-443.
130. Tigrani DY, Weydert JA. Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations. Am J Clin Pathol 2007;127:580-4.
131. Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008;3:851-7.
132. Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85:265-72; discussion 272.
133. Park EK, Sandrini A, Yates DH, et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008;178:832-7.
134. Pass HI, Carbone M. Current Status of Screening for Malignant Pleural Mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:97-104.
135. Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 2009;18:646-50.
136. Hollevoet K, Nackaerts K, Thimpont J, et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 2010;181:620-5.
137. Park EK, Thomas PS, Yates DH. Biomarkers for early detection of mesothelioma in asbestos-exposed subjects. Clin Chem Lab Med 2010;48:1673-4.
138. Rai AJ, Flores RM, Mathew A, et al. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: Analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med 2010;48:271-8.
139. Hollevoet K, Van Cleemput J, Thimpont J, et al. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study. J Thorac Oncol 2011;6:889-95.
140. Creaney J, Francis RJ, Dick IM, et al. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res 2011;17:1181-9.
141. Shiomi K, Shiomi S, Ishinaga Y, et al. Impact of renal failure on the tumor markers of mesothelioma, N-ERC/mesothelin and osteopontin. Anticancer Res 2011;31:1427-30.
142. Roe OD, Creaney J, Lundgren S, et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer 2008;61:235-43.
143. Boudville N, Paul R, Robinson BW, et al. Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening. Lung Cancer 2011;73:320-4.
144. Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012;30:1541-9.
145. Klebe S, Henderson DW. Early stages of mesothelioma, screening and biomarkers. Recent Results Cancer Res 2011;189:169-93.
146. Kao SC, Reid G, van Zandwijk N, et al. Molecular biomarkers in malignant mesothelioma: state of the art. Pathology 2011;43:201-12.
147. van der Bij S, Schaake E, Koffijberg H, et al. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer 2011;104:1325-33.
148. Bégueret H, Galateau-Salle F, Guillou L, et al. Primary intrathoracic synovial sarcoma: a clinicopathologic study of 40 t(X;18)-positive cases from the French Sarcoma Group and the Mesopath Group. Am J Surg Pathol 2005;29:339-46.
149. Weinbreck N, Vignaud JM, Begueret H, et al. SYT-SSX fusion is absent in sarcomatoid mesothelioma allowing its distinction from synovial sarcoma of the pleura. Mod Pathol 2007;20:617-21.
150. Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976;31:15-24.
151. Mattson K. Natural history and clinical staging of malignant mesothelioma. Eur J Respir Dis 1982;63:87-91.
152. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients: Part 1: Diagnosis. Cancer 1993;72:389-93.
153. Sugarbaker DJ, Strauss GM, Lynch TJ, et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993;11:1172-8.
154. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108:1122-8.
155. Burgers JA, Damhuis RA. Prognostic factors in malignant mesothelioma. Lung Cancer 2004;45 Suppl 1:S49-54.
156. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999;68:1799-804.
157. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788-95.
158. Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur J Cardiothorac Surg 2002;22:298-305.
159. Stewart DJ, Martin-Ucar A, Pilling JE, et al. The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. Ann Thorac Surg 2004;78:245-52.
160. Tammilehto L, Kivisaari L, Salminen US, et al. Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: an assessment in 88 patients. Lung Cancer 1995;12:25-34.
161. Nowak AK, Armato SG 3rd, Ceresoli GL, et al. Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group. Lung Cancer 2010;70:1-6.
162. Rusch VW, Giroux D, Kennedy C, et al. Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database. J Thorac Oncol 2012;7:1631-9.
163. Rusch VW, Godwin JD, Shuman WP. The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1988;96:171-7.
164. Basu S, Saboury B, Torigian DA, et al. Current Evidence Base of FDG-PET/CT Imaging in the Clinical Management of Malignant Pleural Mesothelioma: Emerging Significance of Image Segmentation and Global Disease Assessment. Mol Imaging Biol 2011;13:801-11.
165. Schouwink JH, Kool LS, Rutgers EJ, et al. The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. Ann Thorac Surg 2003;75:1715-8; discussion 1718-9.
166. Alvarez JM, Hasani A, Segal A, et al. Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy. ANZ J Surg 2009;79:734-8.
167. Wilcox BE, Subramaniam RM, Peller PJ, et al. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer 2009;10:244-8.
168. Maasilta P, Kivisaari L, Holsti LR, et al. Radiographic chest assessment of lung injury following hemithorax irradiation for pleural mesothelioma. Eur Respir J 1991;4:76-83.
169. Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2003;126:11-6.
170. de Perrot M, Uy K, Anraku M, et al. Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2007;133:111-6.
171. Pilling J, Dartnell JA, Lang-Lazdunski L. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma. Thorac Cardiovasc Surg 2010;58:215-9.
172. Plathow C, Staab A, Schmaehl A, et al. Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results. Invest Radiol 2008;43:737-44.
173. Sharif S, Zahid I, Routledge T, et al. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg 2011;12:806-11.
174. Erasmus JJ, Truong MT, Smythe WR, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg 2005;129:1364-70.
175. Heelan RT, Rusch VW, Begg CB, et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol 1999;172:1039-47.
176. Edwards JG, Stewart DJ, Martin-Ucar A, et al. The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma. J Thorac Cardiovasc Surg 2006;131:981-7.
177. Sørensen JB, Ravn J, Loft A, et al. Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy. Eur J Cardiothorac Surg 2008;34:1090-6.
178. Mineo TC, Ambrogi V, Pompeo E, et al. The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma. Ann Thorac Surg 2008;85:1740-6.
179. Rice DC, Erasmus JJ, Stevens CW, et al. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg 2005;80:1988-92; discussion 1992-3.
180. Tournoy KG, Burgers SA, Annema JT, et al. Transesophageal endoscopic ultrasound with fine needle aspiration in the preoperative staging of malignant pleural mesothelioma. Clin Cancer Res 2008;14:6259-63.
181. Rice DC, Steliga MA, Stewart J, et al. Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma. Ann Thorac Surg 2009;88:862-8; discussion 8-9.
182. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007;84:1685-92; discussion 1692-3.
183. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-31.
184. Francart J, Vaes E, Henrard S, et al. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. Eur J Cancer 2009;45:2304-11.
185. Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010;16:5805-13.
186. Pinato DJ, Mauri FA, Ramakrishnan R, et al. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol 2012;7:587-94.
187. Nojiri S, Gemba K, Aoe K, et al. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jpn J Clin Oncol 2011;41:32-9.
188. Schneider J, Hoffmann H, Dienemann H, et al. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 2008;3:1317-24.
189. Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007;13:2928-35.
190. Francis RJ, Byrne MJ, van der Schaaf AA, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007;48:1449-58.
191. Nowak AK, Francis RJ, Phillips MJ, et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res 2010;16:2409-17.
192. Ceresoli GL, Chiti A, Zucali PA, et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol 2006;24:4587-93.
193. Veit-Haibach P, Schaefer NG, Steinert HC, et al. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer 2010;67:311-7.
194. Gerbaudo VH, Mamede M, Trotman-Dickenson B, et al. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival. Eur J Nucl Med Mol Imaging. 2011;38:810-21.
195. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-9.
196. Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol 2010;5:1841-8.
197. Musk AW, Olsen N, Alfonso H, et al. Predicting survival in malignant mesothelioma. Eur Respir J 2011;38:1420-4.
198. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002;38:111-21.
199. Baas P. Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Semin Oncol 2002;29:62-9.
200. Ellis P, Davies AM, Evans WK, et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006;1:591-601.
201. Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008;371:1685-94.
202. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
203. Carteni G, Manegold C, Garcia GM, et al. Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 2009;64:211-8.
204. Fennell DA, Gaudino G, O'Byrne KJ, et al. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008;5:136-47.
205. O'Brien ME, Watkins D, Ryan C, et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006;17:270-5.
206. van den Bogaert DP, Pouw EM, van Wijhe G, et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2006;1:25-30.
207. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698-704.
208. Razak ARA, Chatten KJ, Hughes AN. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option. Lung Cancer 2008;60:294-7.
209. Ceresoli GL, Zucali PA, Gianoncelli L, et al. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 2010;36:24-32.
210. Jakobsen JN, Sorensen JB. Review on clinical trials of targeted treatments in malignant mesothelioma. Cancer Chemother Pharmacol 2011;68:1-15.
211. Ho M, Hassan R, Zhang J, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005;11:3814-20.
212. Robinson BW, Robinson C, Lake RA. Localised spontaneous regression in mesothelioma -- possible immunological mechanism. Lung Cancer 2001;32:197-201.
213. Lew F, Tsang P, Holland JF, et al. High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma. J Clin Immunol 1986;6:225-33.
214. Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med 2010;181:1383-90.
215. Hassan R, Sharon E, Pastan I. Mesothelin targeted chemo-immunotherapy for treatment of malignant mesothelioma and lung adenocarcinoma. Ann Oncol 2010;21:ii42.
216. Vachani A, Moon E, Albelda SM. Gene therapy for mesothelioma. Curr Treat Options Oncol 2011;12:173-80.
217. Grossebner MW, Arifi AA, Goddard M, et al. Mesothelioma--VATS biopsy and lung mobilization improves diagnosis and palliation. Eur J Cardiothorac Surg 1999;16:619-23.
218. Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006;29:829-38.
219. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004;(1):CD002916.
220. Soysal O, Karaoglanoglu N, Demiracan S, et al. Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur J Cardiothorac Surg 1997;11:210-3.
221. Halstead JC, Lim E, Venkateswaran RM, et al. Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma. Eur J Surg Oncol 2005;31:314-20.
222. Yan TD, Cao CQ, Boyer M, et al. Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience. Ann Thorac Cardiovasc Surg 2011;17:243-9.
223. Grondin SC, Sugarbaker DJ. Pleuropneumonectomy in the treatment of malignant pleural mesothelioma. Chest 1999;116:450S-4S.
224. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18:1196-202.
225. Sharif S, Zahid I, Routledge T, et al. Extrapleural pneumonectomy or supportive care: Treatment of malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg 2011;12:1040-5.
226. von Meyenfeldt EM, Gooiker GA, van Gijn W, et al. The relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: a systematic review and meta-analysis. J Thorac Oncol 2012;7:1170-8.
227. Chowdhury MM, Dagash H, Pierro A. A systematic review of the impact of volume of surgery and specialization on patient outcome. Br J Surg 2007;94:145-61.
228. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991;102:1-9.
229. Stewart DJ, Martin-Ucar AE, Edwards JG, et al. Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risks of induction chemotherapy, right-sided procedures and prolonged operations. Eur J Cardiothorac Surg 2005;27:373-8.
230. Cao CQ, Yan TD, Bannon PG, et al. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 2010;5:1692-703.
231. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63; discussion 63-5.
232. Sugarbaker DJ, Garcia JP. Multimodality therapy for malignant pleural mesothelioma. Chest 1997;112:272S-5S.
233. Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: Results from an EORTC phase II multicentre trial. Eur Respir J 2010;36:1362-9.
234. Weder W, Opitz I, Stahel R. Multimodality strategies in malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:172-6.
235. Sugarbaker DJ, Norberto JJ. Multimodality management of malignant pleural mesothelioma. Chest 1998;113:61S-5S.
236. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006;1:289-95.
237. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763-72.
238. Weder W, Stahel RA, Baas P, et al. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 2011;12:1093-4; author reply 4-5.
239. Hasani A, Alvarez JM, Wyatt JM, et al. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol 2009;4:1010-6.
240. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620-6, 626.e1-3.
241. Nakas A, Trousse DS, Martin-Ucar AE, et al. Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg 2008;34:886-91.
242. Maziak DE, Gagliardi A, Haynes AE, et al. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 2005;48:157-69.
243. Okada M, Mimura T, Ohbayashi C, et al. Radical surgery for malignant pleural mesothelioma: results and prognosis. Interact Cardiovasc Thorac Surg 2008;7:102-6.
244. Pass HI, Kranda K, Temeck BK, et al. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann Surg Oncol 1997;4:215-22.
245. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007-13.
246. Ceresoli GL, Locati LD, Ferreri AJ, et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 2001;34:279-87.
247. Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006;24:1561-7.
248. Price A. What is the role of radiotherapy in malignant pleural mesothelioma? Oncologist 2011;16:359-65.
249. Gordon W Jr, Antman KH, Greenberger JS, et al. Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys 1982;8:19-25.
250. Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol 1990;13:4-9.
251. Davis SR, Tan L, Ball DL. Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation. Australas Radiol 1994;38:212-4.
252. de Graaf-Strukowska L, van der Zee J, van Putten W, et al. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys 1999;43:511-6.
253. Jenkins P, Milliner R, Salmon C. Re-evaluating the role of palliative radiotherapy in malignant pleural mesothelioma. Eur J Cancer 2011;47:2143-9.
254. Waite K, Gilligan D. The role of radiotherapy in the treatment of malignant pleural mesothelioma. Clin Oncol (R Coll Radiol) 2007;19:182-7.
255. Ung YC, Yu E, Falkson C, et al. The role of radiation therapy in malignant pleural mesothelioma: a systematic review. Radiother Oncol 2006;80:13-8.
256. Chapman E, Garcia Dieguez M. Radiotherapy for malignant pleural mesothelioma (Review). Cochrane Database of Systematic Reviews 2010. Available online: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003880.pub4/pdf/standard (cited 15 Sept 2011).
257. Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2005;63:1045-52.
258. Stevens CW, Forster KM, Smythe WR, et al. Radiotherapy for mesothelioma. Hematol Oncol Clin North Am 2005;19:1099-115, vii.
259. Maasilta P. Deterioration in lung function following hemithorax irradiation for pleural mesothelioma. Int J Radiat Oncol Biol Phys 1991;20:433-8.
260. Kutcher GJ, Kestler C, Greenblatt D, et al. Technique for external beam treatment for mesothelioma. Int J Radiat Oncol Biol Phys 1987;13:1747-52.
261. Gupta V, Krug LM, Laser B, et al. Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. J Thorac Oncol 2009;4:746-50.
262. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997;63:334-8.
263. Ahamad A, Stevens CW, Smythe WR, et al. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J 2003;9:476-84.
264. Rice DC, Smythe WR, Liao Z, et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2007;69:350-7.
265. Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006;65:640-5.
266. Kristensen CA, Nottrup TJ, Berthelsen AK, et al. Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. Radiother Oncol 2009;92:96-9.
267. Allen AM, Schofield D, Hacker F, et al. Restricted field IMRT dramatically enhances IMRT planning for mesothelioma. Int J Radiat Oncol Biol Phys 2007;69:1587-92.
268. Miles EF, Larrier NA, Kelsey CR, et al. Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. Int J Radiat Oncol Biol Phys 2008;71:1143-50.
269. Chi A, Liao Z, Nguyen NP, et al. Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma. J Thorac Oncol 2011;6:1132-41.
270. Feigen M, Lee ST, Lawford C, et al. Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F-FDG PET/CT scan correlation. J Med Imaging Radiat Oncol 2011;55:320-32.
271. NCCN Guidelines for Treatment of Cancer by Site: Malignant Pleural Mesothelioma. National Comprehensive Cancer Network. Available online: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
272. Low EM, Khoury GG, Matthews AW, et al. Prevention of tumour seeding following thoracoscopy in mesothelioma by prophylactic radiotherapy. Clin Oncol (R Coll Radiol) 1995;7:317-8.
273. De Ruysscher D, Slotman B. Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey. Radiother Oncol 2003;68:299-302.
274. Lee C, Bayman N, Swindell R, et al. Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice. Lung Cancer 2009;66:150-6.
275. Nagendran M, Pallis A, Patel K, et al. Should all patients who have mesothelioma diagnosed by video-assisted thoracoscopic surgery have their intervention sites irradiated? Interact Cardiovasc Thorac Surg 2011;13:66-9.
276. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995;108:754-8.
277. Bydder S, Phillips M, Joseph DJ, et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 2004;91:9-10.
278. O'Rourke N, Garcia JC, Paul J, et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007;84:18-22.
279. McAleer MF, Tsao AS, Liao Z. Radiotherapy in malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2009;75:326-37.
280. Standards for Providing Quality Palliative Care for all Australians. Canberra: Palliative Care Australia, 2005.
281. Nowak AK, Stockler MR, Byrne MJ. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. J Clin Oncol 2004;22:3172-80.
282. Hillerdal G. Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest 1983;77:321-43.
283. Zimmermann C, Riechelmann R, Krzyzanowska M, et al. Effectiveness of specialized palliative care: a systematic review. JAMA 2008;299:1698-709.
284. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-42.
285. Waller A, Girgis A, Johnson C, et al. Implications of a needs assessment intervention for people with progressive cancer: impact on clinical assessment, response and service utilisation. Psychooncology 2012;21:550-7.
286. Cancer pain relief. World Health Organization. 1986. Available from: http://www.who.int/iris/handle/10665/43944 (cited 15 Sept 2011).
287. Ahmedzai SH, Baldwin DR, Currow DC. Supportive Care in Respiratory Disease. Second ed: Oxford University Press, 2012:400.
288. Jackson MB, Pounder D, Price C, et al. Percutaneous cervical cordotomy for the control of pain in patients with pleural mesothelioma. Thorax 1999;54:238-41.
289. Kanpolat Y, Savas A, Ucar T, et al. CT-guided percutaneous selective cordotomy for treatment of intractable pain in patients with malignant pleural mesothelioma. Acta Neurochir (Wien) 2002;144:595-9.
290. Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002;57:939-44.
291. Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003;327:523-8.
292. Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage 2011;42:388-99.
293. Bausewein C, Booth S, Gysels M, et al. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. The Cochrane Collaboration, 2011.
294. Lee YC, Fysh ET. Indwelling pleural catheter: changing the paradigm of malignant effusion management. J Thorac Oncol 2011;6:655-7.
295. Suzuki K, Servais EL, Rizk NP, et al. Palliation and pleurodesis in malignant pleural effusion: the role for tunneled pleural catheters. J Thorac Oncol 2011;6:762-7.
296. Uronis HE, Currow DC, McCrory DC, et al. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis. Br J Cancer 2008;98:294-9.
297. Ben-Aharon I, Gafter-Gvili A, Paul M, et al. Interventions for alleviating cancer-related dyspnea: a systematic review. J Clin Oncol 2008;26:2396-404.
298. Galbraith S, Fagan P, Perkins P, et al. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J Pain Symptom Manage 2010;39:831-8.
299. Isenring E, Hill J, Davidson W, et al. Evidence-based practice guidelines for the nutritional management of patients receiving radiation therapy. Nutrition and Dietetics 2008;65:S1-S20.
300. Hollen PJ, Gralla RJ, Liepa AM, et al. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: Using the LCSS-Meso conceptual model for validation. Cancer 2004;101:587-95.
301. Survey of mesothelioma patients and their carers. British Lung Foundation. 2009. Available online: www.blf.org.uk/Publication/Detail/mesothelioma (cited 24 Jan 2012).
302. Lee SF, O'Connor MM, Chapman Y, et al. A very public death: dying of mesothelioma and asbestos-related lung cancer (M/ARLC) in the Latrobe Valley, Victoria, Australia. Rural Remote Health 2009;9:1183.
303. Hughes N, Arber A. The lived experience of patients with pleural mesothelioma. Int J Palliat Nurs 2008;14:66-71.
304. Clayson H, Seymour J, Noble B. Mesothelioma from the patient's perspective. Hematol Oncol Clin North Am 2005;19:1175-90, viii.
305. Clinical practice guidelines for the psychosocial care of adults with cancer. Canberra: National Breast Cancer Centre 2003.
306. Schofield P, Carey M, Love A, et al. 'Would you like to talk about your future treatment options'? Discussing the transition from curative cancer treatment to palliative care. Palliat Med 2006;20:397-406.
307. Schofield P, Diggens J, Charleson C, et al. Effectively discussing complementary and alternative medicine in a conventional oncology setting: communication recommendations for clinicians. Patient Educ Couns 2010;79:143-51.
308. Hudson PL, Schofield P, Kelly B, et al. Responding to desire to die statements from patients with advanced disease: recommendations for health professionals. Palliat Med 2006;20:703-10.
309. Kissane DW, Bylund CL, Banerjee SC, et al. Communication skills training for oncology professionals. J Clin Oncol 2012;30:1242-7.
310. Uitterhoeve RJ, Bensing JM, Grol RP, et al. The effect of communication skills training on patient outcomes in cancer care: a systematic review of the literature. Eur J Cancer Care (Engl) 2010;19:442-57.
311. Paul CL, Clinton-McHarg T, Sanson-Fisher RW, et al. Are we there yet? The state of the evidence base for guidelines on breaking bad news to cancer patients. Eur J Cancer 2009;45:2960-6.
312. Dooley JJ, Wilson JP, Anderson VA. Stress and depression of facing death: Investigation of psychological symptoms in patients with mesothelioma. Aust J Psychol 2010;62:160-8.
313. Carlson LE, Waller A, Mitchell AJ. Screening for distress and unmet needs in patients with cancer: review and recommendations. J Clin Oncol 2012;30:1160-77.
314. Moore S, Darlison L, Tod AM. Living with mesothelioma. A literature review. Eur J Cancer Care (Engl) 2010;19:458-68.
315. Palmer C, Thain C. Strategies to ensure effective and empathetic delivery of bad news. Cancer Nursing Practice 2010;9:24-7.
316. Moore S, Teehan C, Cornwall A, et al. 'Hands of Time': the experience of establishing a support group for people affected by mesothelioma. Eur J Cancer Care (Engl) 2008;17:585-92.
317. Hawley R, Monk A. Malignant mesothelioma: current practice and research directions. Collegian 2004;11:22-6.
318. Abrahm JL. Palliative care for the patient with mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:164-71.
319. Chapman E, Hughes D, Landy A, et al. Challenging the representations of cancer pain: experiences of a multidisciplinary pain management group in a palliative care unit. Palliat Support Care 2005;3:43-9.
320. Lebovits AH, Chahinian AP, Holland JC. Exposure to asbestos: psychological responses of mesothelioma patients. Am J Ind Med 1983;4:459-66.
321. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998;83:777-82.
322. Girgis A, Adams J, Sibbritt D. The use of complementary and alternative therapies by patients with cancer. Oncol Res 2005;15:281-9.
323. Schofield PE, Juraskova I, Butow PN. How oncologists discuss complementary therapy use with their patients: an audio-tape audit. Support Care Cancer 2003;11:348-55.
324. Tasaki K, Maskarinec G, Shumay DM, et al. Communication between physicians and cancer patients about complementary and alternative medicine: exploring patients' perspectives. Psychooncology 2002;11:212-20.
325. Hong NJ, Wright FC, Gagliardi AR, et al. Examining the potential relationship between multidisciplinary cancer care and patient survival: an international literature review. J Surg Oncol 2010;102:125-34.
326. Riedel RF, Wang X, McCormack M, et al. Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care. J Thorac Oncol 2006;1:692-6.
327. Leo F, Venissac N, Poudenx M, et al. Multidisciplinary management of lung cancer: how to test its efficacy? J Thorac Oncol 2007;2:69-72.
328. Kendall M, Boyd K, Campbell C, et al. How do people with cancer wish to be cared for in primary care? Serial discussion groups of patients and carers. Fam Pract 2006;23:644-50.
329. Gorman DR, Mackinnon H, Storrie M, et al. The general practice perspective on cancer services in Lothian. Fam Prac 2000;17:323-8.
330. Mitchell GK. The role of general practice in cancer care. Aust Fam Physician 2008;37:698-702.
331. Hall SE, Holman CD, Threlfall T, et al. Lung cancer: An exploration of patient and general practitioner perspectives on the realities of care in rural Western Australia. Aust J Rural Health 2008;16:355-62.
332. Vinod SK, Delaney GP, Bauman AE, et al. Lung cancer patterns of care in south western Sydney, Australia. Thorax 2003;58:690-4.
333. Olsson JK, Schultz EM, Gould MK. Timeliness of care in patients with lung cancer: A systematic review. Thorax 2009;64:749-56.
334. Mooney K, King A. Lung Cancer: The patient's journey. J Thorac Oncol 2011;6:S30.
335. Fischel RJ, Dillman RO. Developing an effective lung cancer program in a community hospital setting. Clin Lung Cancer 2009;10:239-43.
336. Luxford T, Vinod S, Koh E, et al. Use of a validated assessment tool in lung cancer patients to identify symptom burden: the value of a nursing-led care coordination model. Asia Pac J Clin Oncol 2009;5:A168.
337. Martin-Ucar AE, Waller DA, Atkins JL, et al. The beneficial effects of specialist thoracic surgery on the resection rate for non-small-cell lung cancer. Lung Cancer 2004;46:227-32.
338. Simunovic M, Rempel E, Thériault ME, et al. Influence of hospital characteristics on operative death and survival of patients after major cancer surgery in Ontario. Can J Surg 2006;49:251-8.
339. Bach PB, Cramer LD, Schrag D, et al. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001;345:181-8.
340. Barocas DA, Mitchell R, Chang SS, et al. Impact of surgeon and hospital volume on outcomes of radical prostatectomy. Urol Oncol 2010;28:243-50.
341. Chen CS, Liu TC, Lin HC, et al. Does high surgeon and hospital surgical volume raise the five-year survival rate for breast cancer? A population-based study. Breast Cancer Res Treat 2008;110:349-56.
342. Sosa JA, Bowman HM, Gordon TA, et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg 1998;228:429-38.
343. Finlayson EV, Birkmeyer JD. Effects of hospital volume on life expectancy after selected cancer operations in older adults: a decision analysis. J Am Coll Surg 2003;196:410-7.
344. Rogers SO Jr, Wolf RE, Zaslavsky AM, et al. Relation of surgeon and hospital volume to processes and outcomes of colorectal cancer surgery. Ann Surg 2006;244:1003-11.
345. Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol 2000;18:2327-40.
346. Kim SY, Park JH, Kim SG, et al. Disparities in utilization of high-volume hospitals for cancer surgery: results of a Korean population-based study. Ann Surg Oncol 2010;17:2806-15.
347. Lien YC, Huang MT, Lin HC. Association between surgeon and hospital volume and in-hospital fatalities after lung cancer resections: the experience of an Asian country. Ann Thorac Surg 2007;83:1837-43.
348. Yan TD, Boyer M, Tin MM, et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg 2009;138:619-24.